PCC
SPRY icon

Park Circle Company’s ARS Pharmaceuticals SPRY Stock Holding History

Park Circle Company’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,000
Closed -$20.1K – 68
2025
Q3 		$20.1K Hold
2,000
– – 0.02% 62
2025
Q2 		$34.9K Hold
2,000
– – 0.03% 83
2025
Q1 		$25.2K Hold
2,000
– – 0.02% 87
2024
Q4 		$21.1K Hold
2,000
– – 0.02% 89
2024
Q3 		$29K Hold
2,000
– – 0.03% 82
2024
Q2 		$17K Hold
2,000
– – 0.02% 95
2024
Q1 		$20.4K Hold
2,000
– – 0.02% 87
2023
Q4 		$11K Hold
2,000
– – 0.01% 104
2023
Q3 		$7.56K Buy
+2,000
New +$13.1K 0.01% 104

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Park Circle Company's SPRY Position: Q4 2025 in Review

Park Circle Company sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 2,000 shares — an estimated $20.1K sold.

Park Circle Company first reported a position in SPRY in Q3 2023 and held it in 9 quarters. The position peaked at $34.9K in Q2 2025. 189 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Park Circle Company reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Park Circle Company sold 2,000 ARS Pharmaceuticals shares in Q4 2025, an estimated $20.1K.
  • Park Circle Company first reported a position in ARS Pharmaceuticals in Q3 2023 and held it in 9 quarters.
  • Park Circle Company's ARS Pharmaceuticals position peaked at $34.9K in Q2 2025.
  • 189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Park Circle Company's 13F filing for Q4 2025, filed 13 Feb 2026.